Author

Floriane Montanari

ORCID 0000-0002-4676-6170Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:machine learning (classical)· 1 Assay:proteomics· 1

Frequent Co-Authors

Lucia PattariniiD· 2 shared Agnes KnopfiD· 1 shared Alberto RomagnoniiD· 1 shared Alex J. CornishiD· 1 shared Alexandra HardyiD· 1 shared Alexandre GrimaldiiD· 1 shared Alice Mac KainiD· 1 shared Almoatazbellah YoussefiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Lucia PattariniORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMay 15, 2026

Identification of non-covalent inhibitors for the atypical peroxiredoxin PRDX5 as a therapeutic strategy in malignant pleural mesothelioma

Josep Monserrat, Floriane Montanari, Victor Laurent…·Elodie Pronier

The paper identifies non-covalent inhibitors of PRDX5, a protein upregulated in MPM, through a machine learning guided pipeline and biochemical validation, suggesting it as a therapeutic target.

DOI 10.64898/2026.05.13.724787

humanproteomics

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintFeb 10, 2026

OKN4395, a first-in-class EP2/EP4/DP1 triple antagonist reprograms prostanoid-driven immunosuppression to restore antitumor immunity

Maximilien Grandclaudon, Morgane Boulch, Anna Thaller…·Andrew J. Pierce

OKN4395, a triple EP2/EP4/DP1 antagonist, restores antitumor immunity by reversing prostanoid-driven immunosuppression and synergizes with anti-PD1 therapy.

DOI 10.64898/2026.02.08.704632

experimental assaydrug response / drug discovery

𝕏 PostBluesky